New insulin aspart put to the test: will it match the original?
NCT ID NCT07600944
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study compares a new rapid-acting insulin (UBLIN®) to the approved NovoRapid® in 44 healthy men. Each participant receives a single dose of both insulins on separate days to see how the body absorbs and responds. The goal is to check if the new insulin works similarly, which could lead to more affordable diabetes treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Insulin aspart (a rapid-acting insulin)
- What this could lead to
- If successful, this could show that the new insulin aspart is similar to the approved version, potentially offering a more affordable option for people with diabetes.
- What could go wrong
- This is an early-stage study in healthy people, not patients with diabetes. It only looks at short-term effects after a single dose, so it cannot predict long-term safety or effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS AND PHARMACODYNAMICS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Xingtai Medical College (Xingtai Cancer Hospital)
Xingtai, Hebei, 054000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.